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Key questions
What is already known about this subject?
 ► Severe aortic stenosis develops insidiously and is 
associated with markedly increased morbidity and 
mortality when not recognised and treated in a time-
ly manner.
What does this study add?
 ► We developed and evaluated a model including age 
and three proteins, N-terminal pro-B-type natriuret-
ic peptide, von Willebrand factor and fetuin-A, which 
identified patients with severe aortic stenosis.
How might this impact on clinical practice?
 ► A model composed of age and three circulating bio-
markers may supplement currently available diag-
nostic methods to facilitate the diagnosis of severe 
aortic valve stenosis and may serve as the basis for 
population screening algorithms.
AbstrAct
Objective Severe aortic valve stenosis (AS) develops via 
insidious processes and can be challenging to correctly 
diagnose. We sought to develop a circulating biomarker 
panel to identify patients with severe AS.
Methods We enrolled study participants undergoing 
coronary or peripheral angiography for a variety of 
cardiovascular diseases at a single academic medical 
centre. A panel of 109 proteins were measured in blood 
obtained at the time of the procedure. Statistical learning 
methods were used to identify biomarkers and clinical 
parameters that associate with severe AS. A diagnostic 
model incorporating clinical and biomarker results was 
developed and evaluated using Monte Carlo cross-
validation.
Results Of 1244 subjects (age 66.4±11.5  years, 28.7% 
female), 80 (6.4%) had severe AS (defined as aortic 
valve area (AVA) <1.0  cm2). A final model included age, 
N-terminal pro-B-type natriuretic peptide, von Willebrand 
factor and fetuin-A. The model had good discrimination 
for severe AS (OR=5.9, 95% CI 3.5 to 10.1, p<0.001) 
with an area under the curve of 0.76 insample and 0.74 
with cross-validation. A diagnostic score was generated. 
Higher prevalence of severe AS was noted in those with 
higher scores, such that 1.6% of those with a score of 
1 had severe AS compared with 15.3% with a score of 
5 (p<0.001), and score values were inversely correlated 
with AVA (r=−0.35; p<0.001). At optimal model cut-off, 
we found 76% sensitivity, 65% specificity, 13% positive 
predictive value and 98% negative predictive value.
Conclusions We describe a novel, multiple biomarker 
approach for diagnostic evaluation of severe AS.
Trial registration number NCT00842868.
InTROduCTIOn
Calcific aortic stenosis (AS) is the most 
common cause of valvular heart disease in 
the Western world, present in >20% of older 
adults.1 As the proportion of elderly Ameri-
cans grows, so too will the prevalence and 
socioeconomic burden of AS. AS progresses 
via an indolent process with symptoms devel-
oping at a late stage of the disease. Once 
symptoms occur, AS portends a dismal prog-
nosis unless the aortic valve is replaced; 
without aortic valve replacement (AVR), only 
half of patients will survive 1 year.2
Current clinical practice guidelines 
recommend deferring AVR until AS severity 
reaches the severe stage and until onset 
of clinical symptoms or the occurrence of 
overt left ventricular (LV) systolic dysfunc-
tion.3 Classic teaching suggests that survival 
normalises after AVR; however, evidence is 
mounting that survival, symptom improve-
ment and quality of life are diminished when 
valve replacement is performed late. With 
progressive valve narrowing, compensatory 
LV remodelling mechanisms fail and become 
maladaptive, in turn resulting in irreversible 
myocardial injury and fibrosis. For example, 
we have demonstrated that the absence of LV 
ejection fraction (LVEF) improvement within 
1 month after transcatheter AVR is associated 
with a tripling of the risk of 1-year all-cause 
mortality and fivefold increase in 1-year 
cardiac death,4 and persistent LV hyper-
trophy is similarly associated with increased 
mortality.5 Myocardial fibrosis, a late sequela 
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of AS, has also been associated with markedly increased 
risk of mortality, regardless of whether the stenotic aortic 
valve is replaced.6
Early recognition of severe AS is important for maxi-
mising health and survival after valve replacement. While 
clinical history is important, symptoms caused by severe 
AS are often incorrectly attributed to comorbid condi-
tions or simply to advanced age, delaying appropriate 
diagnosis and therapy. Physical examination may be 
useful to identify AS and grade its severity, yet skills in 
such evaluation may be limited in clinical practice.7 Echo-
cardiography is the gold-standard diagnostic test for the 
diagnosis and grading of AS severity, yet several incon-
sistencies with the echocardiographic assessment of AS 
exist that may hinder appropriate clinical management 
decisions. Echocardiography is also time-consuming, 
potentially costly and requires specialised interpretation.
Together, the aforementioned observations highlight 
the detrimental impact of delayed intervention for severe 
AS and highlight the need for clinical tools to assist in 
the rapid identification of severe AS. We therefore sought 
to develop a biomarker panel to identify patients with 
severe AS within the Catheter Sampled Blood Archive in 
Cardiovascular Diseases (CASABLANCA) study. Such a 
blood-based biomarker panel may serve as a convenient 
and low-cost method of screening for severe AS.
MeTHOds
The design of the CASABLANCA study has been described 
previously ( ClinicalTrials. gov NCT00842868).8 9 Briefly, 
the CASABLANCA study was a prospective, single-
centre, investigator-initiated, observational cohort study 
performed at the Massachusetts General Hospital to 
investigate novel biomarkers in subjects who under-
went coronary and peripheral angiography with or 
without intervention between 2008 and 2011. Patients 
were referred for these procedures for several reasons, 
including angiography for acute coronary syndromes, 
stable angina, heart failure, abnormal cardiac functional 
test, peripheral arterial disease, and preoperatively before 
heart valve surgery or transcatheter intervention.
All subjects provided informed consent.
data acquisition
Detailed clinical and historical variables and reason for 
referral for angiography were recorded from medical 
record review and subject interviews at the time of 
the procedure. Echocardiographic data from studies 
performed within 6 months of enrolment were collected 
retrospectively. Transthoracic echocardiographic images 
were obtained using standard views for routine clinical 
care. Recorded echocardiographic parameters include 
measures of AS severity (valve area, transvalvular gradi-
ents), LV chamber dimensions, hypertrophic remod-
elling (absolute and relative wall thickness and LV 
mass), systolic and diastolic function, and other valvular 
abnormalities. Measures of AS severity were available in 
patients with at least moderate AS. All measurements 
were performed as outlined by the American Society of 
Echocardiography.10
Biomarker testing
Blood (15 mL) was collected immediately before angi-
ography and after the completion of angiographic 
procedure(s) through a centrally placed vascular access 
sheath. Samples were immediately centrifuged for 15 
min, and plasma samples were then aliquoted on ice 
and frozen in a −80°C refrigerator until analysis. After a 
single freeze–thaw cycle, 200 µL of plasma was analysed 
using the Luminex 100/200 xMAP technology platform 
(Luminex, Austin, Texas), which uses multiplexed, micro-
sphere-based assays in a single reaction vessel. Multi-
plexing was accomplished by assigning each protein-spe-
cific assay a microsphere set labelled with a unique fluo-
rescence signature. An assay-specific capture antibody was 
conjugated covalently to each unique set of microspheres 
and bound to the protein of interest. Assay-specific, bioti-
nylated detecting antibodies were added, followed by a 
streptavidin-labelled fluorescent ‘reporter’ molecule. We 
specifically assayed 109 proteins (online supplementary 
table 1) using a commercially available kit, known as the 
Myriad RBM MAP. The panel incorporates biomarkers 
that reflect a wide variety of pathways associated with 
plaque rupture/erosion and includes acute phase reac-
tants, inflammatory markers and biomarkers of athero-
sclerosis.
statistical analyses
For the purposes of this analysis, subjects were consid-
ered to have severe AS if a transthoracic echocardiogram 
within 6 months of enrolment demonstrated severe AS, 
defined by an aortic valve area (AVA) <1.0 cm2. Since 
AVA is consistently measured in patients with AS, patients 
missing AVA measurements were assumed to be negative. 
Baseline characteristics in those with and without severe 
AS were compared using Fisher’s exact test for categorical 
variables, two-sided two-sample t-test for normally distrib-
uted continuous variables, and Wilcoxon rank-sum test 
for continuous variables that were not normally distrib-
uted. Protein concentrations were log-transformed to 
achieve a normal distribution, and to facilitate the analysis 
they were rescaled to a zero-mean, unit-variance distribu-
tion, and outliers (ie, values beyond 3× median absolute 
deviation) were Winsorised. The case was conducted as 
a complete case analysis, and one patient was excluded 
from the analysis for missing data.
Candidate panels of proteins and clinical features 
were generated via least-angle regression (LARS).8 In 
this method, factors were included in the model one 
at a time, with their coefficients determined by their 
correlation with the outcome. This was repeated until 
all factors were included in the model, and the step at 
which the performance plateaued resulted in our initial 
panel of interest. With this panel of interest, predictive 
analyses were run on the training set using least absolute 
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Table 1 Baseline patient characteristics
Patient characteristics
With severe AS
(n=80)
Without severe AS 
(n=1164) P values
Age, years 73.9±10.6 65.9±11.4 <0.001
Male gender 55/80 (68.8%) 831/1164 (71.4%) 0.61
Caucasian 79/80 (98.8%) 1083/1164 (93.0%) 0.06
Heart rate, beats/min 73±14 69±13 0.01
Systolic BP, mm Hg 137±21 138±23 0.75
Diastolic BP, mm Hg 71±10 73±12 0.16
Smoker 6/80 (7.5%) 172/1151 (14.9%) 0.07
Atrial fibrillation/flutter 23/80 (28.8%) 210/1164 (18.0%) 0.03
Hypertension 63/80 (78.8%) 877/1164 (75.3%) 0.59
Coronary artery disease 35/80 (43.8%) 621/1164 (53.4%) 0.11
Prior MI 12/80 (15.0%) 280/1164 (24.1%) 0.08
Heart failure 22/80 (27.5%) 233/1164 (20.0%) 0.12
Peripheral artery disease 21/80 (26.3%) 306/1164 (26.3%) >0.99
COPD 16/80 (20.0%) 203/1163 (17.5%) 0.55
Diabetes mellitus 25/80 (31.3%) 322/1164 (27.7%) 0.52
CVA/TIA 8/80 (10.0%) 129/1164 (11.1%) >0.99
CKD 16/80 (20.0%) 151/1164 (13.0%) 0.09
Renal replacement therapy 2/80 (2.5%) 34/1161 (2.9%) >0.99
Prior angioplasty 6/80 (7.5%) 157/1164 (13.5%) 0.17
Prior stent 15/80 (18.8%) 373/1164 (32.0%) 0.01
Prior CABG 19/80 (23.8%) 251/1164 (21.6%) 0.67
Medication use 
  ACE-I/ARB 41/78 (52.6%) 641/1161 (55.2%) 0.72
  Beta-blocker 41/79 (51.9%) 836/1161 (71.0%) <0.001
  Aldosterone antagonist 5/79 (6.3%) 50/1161 (4.3%) 0.39
  Loop diuretics 25/79 (31.7%) 239/1161 (20.6%) 0.03
  Nitrates 9/79 (11.4%) 230/1160 (19.8%) 0.08
  CCB 27/79 (34.2%) 288/1161 (24.8%) 0.08
  Statin 59/79 (74.7%) 852/1160 (73. 5%) 0.90
  Aspirin 52/79 (65.8%) 911/1160 (78.5%) 0.01
  Warfarin 15/79 (19.0%) 175/1160 (15.1%) 0.34
  Clopidogrel 10/79 (12.7%) 291/1160 (25.1%) 0.01
Echocardiographic parameters 
  LVEF, % 57.1±15.7 56.4±15.2 0.71
  RSVP, mm Hg 42.1±9.6 41.4±11.9 0.66
Biochemical parameters 
  Creatinine, mg/dL 1.0 (0.9–1.4) 1.09 (0.90–1.33) 0.97
  eGFR*, mL/min/1.73 m2 91.7 (67. 3–107.0) 98.8 (72.7–110.2) 0.06
  Total cholesterol, mg/dL 147.5±50.3 149.9±41.8 0.76
  LDL cholesterol, mg/dL 83.0±40.0 81.4±33.4 0.8
  Glycosylated haemoglobin, % 5.7 (5.4–6.5) 6.2 (5.7–7.1) 0.005
  Glucose, mg/dL 101 (93–109) 102 (92–122) 0.48
  Haemoglobin, g/dL 13.2±1.9 13.2±1.7 0.88
Biomarkers 
Continued
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Patient characteristics
With severe AS
(n=80)
Without severe AS 
(n=1164) P values
  NT-proBNP, pg/mL 4095.0 (1692.5–15 975.0) 1385.0 (523.8–3732.5) <0.001
  von Willebrand factor, μg/mL 124.0 (91.3–175.0) 130.0 (95.0–179.0) 0.40
  Fetuin-A, μg/mL 620.5 (512.3–787.3) 700.0 (585.0–832.3) 0.002
Values are mean±SD, median (IQR) or n/N (%).
*Calculated using the Chronic Kidney Disease-Epidemiology Collaboration formula.
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; AS, aortic stenosis; BP, blood pressure; CABG, coronary artery bypass 
graft surgery; CCB, calcium channel blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVA/TIA, 
cerebrovascular accident/transient ischaemic attack; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; LVEF, left 
ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RVSP, right ventricular systolic 
pressure.
Table 1 Continued
Figure 1 Distribution of NT-proBNP, von Willebrand factor and fetuin-A in patients with and without aortic stenosis. Levels of 
circulating biomarkers are shown in patients without significant AS, moderate AS and severe AS. Dark lines indicate median 
values and grey bar the IQR. Error bars indicate the range of the rest of the distribution to 1.5 times the IQR. AS, aortic 
stenosis; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
shrinkage and selection operator (LASSO) with logistic 
regression, predicting the outcome of severe AS using 
only the variables in the panel of interest. This model 
development process was done via Monte Carlo cross-val-
idation, using 400 iterations with an 80:20 (training:test) 
split. The final panel was used to create a final model with 
the entire sample, and this model was then evaluated to 
predict severe AS. Discrimination of the final model was 
assessed by calculating the area under the receiver oper-
ating curve (AUC), and calibration was determined using 
Akaike or Bayesian information criteria (AIC and BIC, 
respectively) and the Hosmer-Lemeshow goodness of fit 
test. The score of the final model was grouped into quin-
tiles to create a five-level clinical risk score. All statistics 
were performed using R V.3.3 software (R Foundation 
for Statistical Computing, Vienna, Austria); p values are 
two-sided, with a value <0.05 considered significant.
ResulTs
Patient population
We enrolled 1251 subjects who underwent coronary and 
peripheral angiography with and without intervention 
between 2008 and 2011. Overall, 981 subjects underwent 
coronary angiography, 155 peripheral angiography, and 
115 both coronary and peripheral angiography. Of these, 
1244 had available blood samples and clinical data for 
analysis. Subjects were on average 66±11 years old and 
28.8% (358 of 1244) were female.
Table 1 details the characteristics of those subjects with 
(n=80; 6.4%) and without severe AS; of those without 
severe AS, moderate stenosis was present in 2.0% (26 of 
1244). Sex and many comorbid conditions were similar 
between those with and without severe AS. However, 
compared with those without, subjects with severe AS were 
older (74±11 vs 66±11 years) and more often afflicted 
with atrial fibrillation/flutter (28.8 vs 18.0%; p=0.03). 
Patients with severe AS were less likely than those without 
severe AS to have undergone a prior stent (18.8 vs 32.0%; 
p=0.01) and were less often receiving a beta-blocker (51.9 
vs 72.0%; p<0.001) or antiplatelet agent (aspirin: 65.8 vs 
78.5%; p=0.01; clopidogrel: 12.7 vs 25.1%; p=0.01). Loop 
diuretics were more often prescribed with severe AS (31.7 
vs 20.6%; p=0.03).
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Table 2 Model fit characteristics
Model AUC AIC BIC Hosmer-Lemeshow p values
Model 1: age 0.70 558.4 568.6 0.18
Model 2: age+NT-proBNP 0.74 540.5 555.9 0.94
Model 3: age+NT-proBNP+vWF 0.75 530.0 550.5 0.06
Model 4: age+NT-proBNP+vWF+fetuin-A 0.76 530.4 556.0 0.44
AIC, Akaike information criterion; AUC, area under the curve; BIC, Bayesian information criterion; NT-proBNP, N-terminal pro-B-type 
natriuretic peptide; vWF, von Willebrand factor.
Figure 2 Prevalence of severe aortic stenosis (AS) within 
a quintile-based five-level diagnostic score. Increasing 
prevalence of severe AS is noted at higher scores, such 
that 1.6% of those with a score of 1 (lowest risk) had severe 
AS compared with 15.3% with a score of 5 (highest risk) 
(p<0.001).
Model for identification of severe As
LARS was used to identify independent predictors of 
severe AS. These factors included age and concentrations 
of three biomarkers: N-terminal pro-B-type natriuretic 
peptide (NT-proBNP), von Willebrand factor (vWF) and 
fetuin-A. Concentrations of NT-proBNP demonstrated 
direct correlation with AS, with a progressive increase in 
circulating NT-proBNP concentrations with worsening AS 
severity (figure 1; p<0.001, Kruskal-Wallis rank-sum test), 
while concentrations of circulating fetuin-A progressively 
decreased with worse AS (p=0.003). vWF concentra-
tions did not clearly correlate with AS severity (p=0.19), 
although the direction of vWF’s effect in the final model 
was negative, with lower concentrations associated with 
severe AS. Using Monte Carlo cross-validation, this panel 
achieved a cross-validated AUC of 0.74.
A final combined model of age, NT-proBNP, vWF and 
fetuin-A was created using the entire population with 
LASSO with logistic regression. This model was strongly 
predictive of severe AS (OR=5.9, 95% CI 3.5 to 10.1, 
p<0.001). To examine the model’s performance and 
the relative contribution of each parameter, we assessed 
discrimination, calibration and Hosmer-Lemeshow 
goodness of fit for identification of severe AS. Addition 
of biomarkers to age resulted in improved AUC of the 
receiver operating characteristic curve, minimisation of 
AIC and BIC, and with non-significant Hosmer-Leme-
show p values (table 2). This final model demonstrated 
discrimination with an insample AUC of 0.76 (p<0.001).
We examined the distribution of the final model’s diag-
nostic score for each patient with their status for severe 
AS. A clinical risk score was derived from the score gener-
ated by the model, with the five quintiles of the score 
corresponding to a five-level risk score. Higher preva-
lence of severe AS was noted in those with higher scores 
(figure 2), such that 1.6% of those with a risk score of 1 
(lowest risk) had severe AS compared with 15.3% with a 
risk score of 5 (highest risk) (p<0.001). When modelled 
as a continuous measure, higher AS scores were directly 
correlated with the proportion of subjects with severe AS 
(p<0.001) and inversely correlated with AVA (r=−0.35; 
p<0.001).
Receiver operator characteristic analyses were 
performed and operating characteristics calculated 
(figure 3). Using a score cut-off determined by the optimal 
Youden’s Index, we found 76% sensitivity, 65% specificity, 
13% positive predictive value and 98% negative predictive 
value. Likelihood ratio for positive results (LR+) was 2.17 
and 0.37 for negative results (LR−).
We evaluated the levels of circulating biomarkers and 
the AS score within subtypes of severe AS (table 3). We 
found marked differences in the levels of NT-proBNP 
across AS subtype, with the highest levels noted in 
patients with low LVEF, low aortic valve gradient (AVG) 
AS, and the lowest levels in those patients with AS with 
preserved LVEF and low AVG (p<0.001). A similar 
although non-significant pattern of abundance was noted 
for circulating vWF (p=0.055). Fetuin-A was highest in 
the preserved LVEF and low AVG group and lowest in 
those with preserved LVEF and high AVG (p=0.01). The 
AS risk score did not differ between AS subtypes.
dIsCussIOn
The identification of AS may be challenging to recog-
nise and grade. Furthermore, broad application of tools 
to assess presence or severity of AS such as echocardiog-
raphy—although useful—may not be practical in some 
populations. As a consequence, a substantial propor-
tion of valvular heart disease is not diagnosed within the 
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Figure 3 Receiver operating characteristic curve for aortic 
stenosis (AS) score. The AS score demonstrated good 
discrimination with an insample area under the curve (AUC) 
of 0.76. The sensitivity, specificity, positive predictive value 
and negative predictive value at the optimal cut-off are 
depicted.
Table 3 Biomarkers in subtypes of aortic stenosis
Biomarker
Mean AVG ≥40 mm Hg 
(n=46)
LVEF <50% and mean AVG 
<40 mm Hg (n=10)
LVEF ≥50% and mean AVG 
<40 mm Hg (n=17) P values
NT-proBNP 4920 (1677.5–15 975) 15 9755 (11 493.75–15 975) 2080 (898–3410) <0.001
vWF 127 (92.5–171.75) 185.5 (145.5–262) 117 (80–172) 0.055
Fetuin-A 594.5 (499.25–667) 603 (501.75–855.25) 781 (656–872) 0.01
AS risk score 6.24±1.58 6.46±1.21 5.36±1.29 0.08
Values are mean±SD, median (IQR).
AS, aortic stenosis; AVG, aortic valve gradient; LVEF, ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; vWF, von 
Willebrand factor.
general population.11 Availability of a non-invasive, easily 
interpreted and cost-effective tool to screen for the pres-
ence of AS is therefore of clinical value. Using patients 
undergoing coronary and peripheral angiography within 
the CASABLANCA study, we developed and evaluated a 
robust, non-invasive, clinical plus multimarker approach 
for the identification of severe AS. This model, which 
includes age and concentrations of NT-proBNP, vWF and 
fetuin-A, was adapted into a clinically applicable score, 
which performed well within the CASABLANCA study 
cohort with strong sensitivity, specificity and negative 
predictive value. The score may therefore add a novel 
tool to our clinical armamentarium for the identification 
of patients with severe AS, in particular for excluding its 
presence in a patient who might otherwise be suspected 
as suffering from the diagnosis.
AS is an indolent disease that culminates in clinical 
decompensation and necessitates valve replacement, 
without which 1-year mortality is exceedingly high.2 In 
fact, mortality due to untreated symptomatic severe AS 
exceeds that associated with several advanced cancer 
diagnoses. While survival is thought to improve on 
valve replacement, recent evidence suggests persistently 
elevated morbidity and mortality risk in patients treated 
at a late disease state. Adverse outcomes are in part 
driven by irreversible maladaptive LV remodelling and 
fibrosis.4–6 In addition, frailty, sarcopaenia and poor 
functional status worsen with time and contribute to 
diminished survival and recovery after AVR.12 13 Timely 
identification of severe AS is therefore of critical impor-
tance to the maintenance of health in the vulnerable 
elderly population.
A detailed physical examination with cardiac ausculta-
tion is often relied on to screen for valve lesions, including 
severe AS. When cardiac auscultation reveals an abnormal 
heart murmur, an echocardiogram is often performed to 
confirm or exclude a pathological cardiac lesion.3 Unfor-
tunately, limited proficiency with cardiac auscultation 
among practitioners contributes to the underdiagnosis 
of AS.14 15 Furthermore, even with comprehensive echo-
cardiography, the gold-standard diagnostic tool, accurate 
identification and grading of AS severity often prove chal-
lenging due to poor imaging windows, inaccurate quan-
tification of LV outflow tract dimensions and discordant 
metrics of AS severity (ie, AVA, mean gradient and peak 
velocity).16 17 Inconsistencies regarding the evaluation of 
AS severity occur due to measurement error and due to 
the disruption of the physiological relationship between 
AV area and gradient that occurs as a consequence of 
diminished transvalvular flow.3 18 19 Together, these factors 
contribute to the frequent late recognition of severe AS 
and highlight the need for novel objective metrics that 
will supplement current diagnostic strategies and aid in 
the timely recognition of at-risk patients.
While biomarkers may be of prognostic value in those 
with AS, our data add significant understanding regarding 
the role of biomarkers for the diagnosis of AS. Concen-
trations of circulating natriuretic peptides rise with AS 
disease severity due to cardiomyocyte stretch and pres-
sure overload and have been shown to predict survival 
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and clinical outcomes in patients with AS and after tran-
scatheter and surgical AVR.20–22 Clinical practice guide-
lines articulate a possible role for elevated natriuretic 
peptide concentrations to inform surgical intervention in 
asymptomatic patients23; reliance on NT-proBNP has not 
been universally endorsed, however.3 For example, while 
NT-proBNP may be elevated in those with AS, LV hyper-
trophy due to AS may normalise wall stress and therefore 
attenuate the anticipated rise in the biomarker. Because 
there is also considerable overlap in natriuretic peptide 
concentrations across elderly patients with and without 
AS,24 a strategy of integrating NT-proBNP with orthog-
onal biomarkers may inform clinical practice better than 
NT-proBNP alone.
Several studies have demonstrated abnormalities in 
vWF high-molecular-weight multimers in subjects with 
severe AS.25 26 As blood flows through a severely stenotic 
valve, shear forces unfold these multimers, resulting in 
increased susceptibility to proteolytic cleavage.25 The 
resultant haematological deficiencies form the clinical 
basis for the acquired type 2A von Willebrand syndrome 
and gastrointestinal angiodysplasia (Heyde’s syndrome), 
often noted with severe AS,25 which may resolve with alle-
viation of AVG.26 Association between circulating vWF 
concentrations in those with and without severe AS were 
less direct than NT-proBNP; however, vWF concentra-
tions were selected by LARS during the model develop-
ment process, and their presence improved calibration of 
the AS model, supporting the adoption of this biomarker 
into a multimarker approach for AS discrimination.
Fetuin-A is a liver-derived protein that binds and solu-
bilises calcium and phosphate and in turn regulates 
soft tissue mineralisation. Reduced circulating fetuin-A 
concentrations have been implicated as a mediator 
of calcific cardiovascular disease seen in patients with 
end-stage renal disease and valve disease.27 As shown here, 
a recent analysis suggested that patients with AS have 
lower circulating fetuin-A than control subjects.28 Much 
as with NT-proBNP and vWF, fetuin-A concentrations 
were selected by LARS to remain in the final aggregate 
multiple biomarker approach for AS diagnosis, and the 
presence of this protein in the model improved model 
discrimination while maintaining equivalent calibration.
While the size of the CASABLANCA cohort, the large 
number of proteins assayed, and the unbiased and 
methodical statistical approach are strengths of the 
current study, several limitations warrant attention. First, 
the CASABLANCA study enrolled subjects undergoing 
invasive cardiovascular angiography, irrespective of the 
clinical indication. The cohort is therefore diverse with 
low prevalence of severe AS. We anticipate that the clin-
ical application of the AS score in select patients with 
higher pretest probability of having severe AS may result 
in improved model performance. Second, the AS score 
possessed low positive predictive value, a consequence of 
the low prevalence of severe AS within our population. 
Such performance characteristics are commonly noted 
for screening tests applied to the general population.29 
Third, subjects with severe AS undergoing angiography 
were largely symptomatic patients being evaluated for 
AVR. We were consequently not able to examine the 
interplay between the AS score and clinical symptom-
atology. Fourth, the relatively small number of AS cases 
limited the statistical power of our attempts to evaluate 
the value of the AS score in discriminating the degree of 
AS severity or AS subtype (preserved LVEF high gradient 
vs paradoxical preserved LVEF low gradient vs low LVEF 
low gradient AS). Future efforts will seek to externally 
validate the AS score with larger patient cohorts and to 
determine the value of the AS score in aiding the grading 
of AS severity.
In conclusion, we have developed a non-invasive, 
biomarker-supported strategy for screening for severe 
AS. This approach includes age and three protein 
biomarkers indicative of distinct biological pathways 
previously implicated in the pathophysiology of AS. The 
model we describe could theoretically be a cost-effective 
addition to the clinical armamentarium for evaluating 
those with suspected AS, facilitating the identification of 
this high-risk patient cohort and fostering timely valve 
replacement. Further efforts are needed to examine the 
utility of incorporating the predictive model into clinical 
practice.
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